Combined point mutations in codon 12 and 13 of KRAS oncogene in prostate carcinomas

Basit Öğe Kaydı
dc.authoridAlan, Cabir/0000-0002-6024-4475
dc.contributor.authorSılan, Fatma
dc.contributor.authorGultekin, Yener
dc.contributor.authorAtik, Sinem
dc.contributor.authorKilinc, Davran
dc.contributor.authorAlan, Cabir
dc.contributor.authorYildiz, Fazilet
dc.contributor.authorUludağ, Ahmet
dc.date.accessioned2025-01-27T20:24:58Z
dc.date.available2025-01-27T20:24:58Z
dc.date.issued2012
dc.departmentÇanakkale Onsekiz Mart Üniversitesi
dc.description.abstractProstate cancer is a common malignancy that develops by structural mutation(s) and/or other genetic alterations in specific genes.The G to T transversions in codon 12 and C to T transitions in codon 13 of KRAS proto-oncogene are predominant point mutations that occur in about 20% of different cancers in human. In the current study it was aimed to investigate the prevalence and predictive significance of KRAS mutations in patients with prostate carcinomas. In a total of 30 fresh tumoural tissue specimens were investigated in patients with prostate carcinoma. All tumoural specimens were histo-pathologically diagnosed and genotyped for codon 12, 13 KRAS point mutations by reverse hybridisation and direct sequencing methods. KRAS mutations were found in 12 (40%) samples with 29 samples deriving from adenocarcinomas and 1 sample was small cell prostate carcinoma. In 1 (3.44%) sample codon 12 was found to be mutated and in 2 (6.8%) samples codon 13 and in 9 (31%) samples combined codon 12 and 13 were found to be mutated particularly in higher grade of tumoural tissues. Our study, based on representative collection of human prostate tumours, indicates that combined mutations in codons 12 and 13 KRAS are relatively infrequent and most commonly occur in prostate carcinomas.
dc.identifier.doi10.1007/s11033-011-0898-8
dc.identifier.endpage1599
dc.identifier.issn0301-4851
dc.identifier.issn1573-4978
dc.identifier.issue2
dc.identifier.pmid21607617
dc.identifier.scopus2-s2.0-84860344694
dc.identifier.scopusqualityQ2
dc.identifier.startpage1595
dc.identifier.urihttps://doi.org/10.1007/s11033-011-0898-8
dc.identifier.urihttps://hdl.handle.net/20.500.12428/22396
dc.identifier.volume39
dc.identifier.wosWOS:000298751300095
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherSpringer
dc.relation.ispartofMolecular Biology Reports
dc.relation.publicationcategoryinfo:eu-repo/semantics/openAccess
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_WoS_20250125
dc.subjectProstate carcinoma
dc.subjectCombined point mutation
dc.subjectKRAS proto-oncogene
dc.subjectCodon 12 and 13
dc.titleCombined point mutations in codon 12 and 13 of KRAS oncogene in prostate carcinomas
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu